A Meta-analysis on curative effect of Qili Qiangxin Capsules on chronic heart failure
LI Xiong-wen
HU Zhan-rui
LUO Hong-min
YAN Xin-jian
CHEN Xian-kun
Abstract：Objective To review the curative effect of Qili Qiangxin Capsules on chronic congestive heart failure (CHF). Methods The randomized controlled trials (RCT) about Qili Qiangxin Capsules in chronic CHF treatment published before Dec. 31, 2013 were retrieved, and qualified RCT were chosen according to inclusion and exclusion criteria. All included 16 RCT documents were given risk reviewing by using Cochrane bias risk tool, and review index and sample volume were extracted from texts and tables by 2 independent reviewers in intervention group and control group before and after treatment. The weighting average difference and 95%CI were analyzed by using RevMan5.2.7 software. Results There were totally 16 RCT included involved 1422 cases (699 in control group and 723 in intervention group). The results of Meta-analysis showed that Qili Qiangxin Capsules combining routine therapies relieved significantly symptoms, improved clinical efficacy (RR=1.18, 95%CI: 1.13-1.24), increased LVEF (WMD=4.89, 95%CI: 3.03-6.75, P<0.00001), decreased BNP level (WMD=95.86, 95%CI:43.96-147.77, P=0.0003, P<0.00001), increased LVEDd (WMD=3.22, 95%CI:1.64-4.80, P<0.00001), increased effectively 6MWT (WMD=41.44, 95%CI:33.30-49.59, P<0.00001), increased CO (WMD=0.22, 95%CI:0.00-0.44, P=0.05), and decreased the integral of Minnesota Table of Quality of Life (WMD=7.69, 95%CI: 4.39-10.99, P<0.00001). Conclusion The current evidence shows that Qili Qiangxin Capsules has good curative effect on chronic CHF. Because of included RCT with publishing bias, more clinical data are needed to confirm the long-term efficacy of Qiangxin Capsules.
Keywords：Qili Qiangxin CapsulesCongestive heart failureMeta-analysis
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 529-533 )